Targeted drug combo aims to tackle tough stomach cancers
NCT ID NCT07692334
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or gastroesophageal junction cancer that has a specific marker called EGFR. The study enrolls about 28 adults whose cancer has worsened after standard first-line therapy. The goal is to see if the combination can shrink tumors and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- becotatugvedotin (an antibody-drug conjugate targeting EGFR) combined with pucotenlimab (an immunotherapy that blocks PD-1)
- What this could lead to
- If this combination works, it could offer a new second-line treatment option for people with EGFR-positive advanced gastric or gastroesophageal junction cancer who have not responded to initial therapy.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 28 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BECOTATUG VEDOTIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?